In this review:
- Selinexor maintenance in TP53 wild-type endometrial cancer
- Progesterone-based therapy vs. hysterectomy in stage 1 endometrial cancer
- A cancer stem cell functional assay in recurrent platinum-resistant epithelial ovarian cancer
- Secondary cytoreduction in relapsed ovarian cancer
- Fulvestrant + ademaciclib in HR+ endometrial cancer
- BrUOG 354: nivolumab ± ipilimumab for (O)CCC
- Cyclophosphamide + bevacizumab in recurrent ovarian cancer
- BEV1L: first-line bevacizumab + chemotherapy in high-risk ovarian cancer
- Neoadjuvant sintilimab + paclitaxel & cisplatin for locally advanced cervical cancer
- Long-term recurrent ovarian cancer survivors with mirvetuximab soravtansine
Please login below to download this issue (PDF)